MEDIFAST INC (MED) Form 8-K — Oct 26, 2026
Medifast reported Q3 2026 revenue of $72.0 million, down 19.4% from $89.4 million a year earlier, with a GAAP net loss of $17.5 million ($1.57 per share) and a non-GAAP adjusted net loss of $2.1 million ($0.19 per share). Revenue was in line with guidance, and the loss was driven largely by $15.4 million of Catalyst restructuring charges tied to simplifying the distribution network and organization. Active earning coaches fell 47.7% year-over-year to 10,200, which management attributed to continued client-acquisition pressure from rapid GLP-1 medication adoption, though revenue per coach rose 54.1% to $7,064. The company expects coach counts to keep declining through the end of 2026.
Key figures
- Revenue
- 72048000
- Guidance
- Q4 2026 revenue $55M-$75M, Q4 EPS $0.00-$0.25; FY2026 revenue $280M-$300M, FY GAAP loss per share $1.80-$2.05, non-GAAP loss per share $0.45-$0.70; FY Adjusted EBITDA excluding interest income $10M-$14M
- Total Debt
- 0
- Total Assets
- 239763000
- Cash Position
- 172500000
- Shares Outstanding
- 11183000
- Adjusted ebitda
- 362000
- Active earning coaches
- 10200
- Revenue per active coach
- 7064
- Adjusted ebitda ex interest
- 1870000
- Catalyst restructuring charges
- 15406000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.